Cisplatin is a widely used anticancer drug that acts by binding DNA and causing the formation of intrastrand and interstrand (ICL) cross-links, but the precise downstream effects of the latter damage are not well understood. In this study, we investigated the influence of cisplatin ICLs on synthetic nucleosomes that were platinated in a site-specific manner in vitro and on gene transcription in live mammalian cells. Nucleosome core particles (NCPs) that we constructed 
Introduction
Platinum-based chemotherapy has been successfully used to treat various types of cancer extensively studied (7) .
In a eukaryotes, DNA wraps around histone octamers forming nucleosomes, the fundamental building blocks of chromatin (8) . Cisplatin binds both free and nucleosomal DNA (9) . Determining the consequences of platinum-DNA adduct formation at the nucleosome level is an important step in understanding the details of cellular recognition of platinum drugs and of transcription stalling. With the use of DNA probes containing site-specific cisplatin lesions, hydroxyl radical footprinting experiments revealed that a cisplatin 1,2-d(GpG) or a 1, intrastrand cross-link overrides the rotational setting predefined in a nucleosome positioning sequence. The lesions face inward, toward the histone core, and affect the translational positioning of the DNA (10) (11) (12) .
Cisplatin ICLs induce profound structural changes in free DNA duplexes and display a profile of binding to cellular proteins and a repair mechanism that are distinct from those of intrastrand cross-links (13) (14) (15) (16) (17) . Relatively little is known about the effects of ICLs at the nucleosome level. Cisplatin forms ICLs on nucleosomal DNA, with the level of cross-linking 4 decreasing near the nucleosome dyad (18) . Other ICL-forming chemotherapeutic agents, such as nitrogen mustards and mitomycin C, also cross-link DNA at levels that diminish near the dyad (19) . Minor groove DNA-binding agents such as pyrrole-imidazole polyamides block temperature-induced histone octamer repositioning and inhibit transcription by bacteriophage T7
RNA polymerase (20, 21) .
The transcription inhibition effects of cisplatin intrastrand cross-links have been extensively explored in both in vitro reconstituted systems and live mammalian cells (22) . To obtain sitespecifically platinated mammalian expression vectors for the latter studies, a "gapping" strategy was employed to incorporate cisplatin intrastrand cross-links within the multiple cloning site of a Gaussia luciferase plasmid, pGLuc (23) . The plasmid was used to investigate transcription inhibition at cisplatin intrastrand cross-links in live mammalian cells (24) . Subsequently, pGLuc containing a site-specific Pt-DNA lesion by a monofunctional platinum compound, pyriplatin
[cis-diammine(pyridine)chloroplatinum(II)], was synthesized and its transcription inhibition effects and repair mechanism were evaluated (25) . The "gapping" strategy is, however, not applicable for the synthesis of plasmids containing site-specific cisplatin ICLs.
Although their frequency is relatively low, cisplatin ICLs have long been a topic of interest (26) . For instance, despite their limited occurrence, ICLs have the potential to be the most critical cisplatin lesion. ICLs have been associated with cisplatin resistance arising from genespecific repair (17) . Despite efforts to understand the cellular recognition and processing of cisplatin ICLs, their repair mechanism(s) in mammalian systems are not well established.
Transcription inhibition studies in vitro reveal that cisplatin ICLs significantly stall both prokaryotic and eukaryotic RNA polymerases at the site of damage (27) .
In order to probe the effects of cisplatin ICLs at the level of the nucleosome we posed the 
Materials and Methods
Enzymes were obtained from New England Biolabs (Ipswich, MA) and chemicals and solvents from commercial sources unless specified otherwise. UV-vis spectra were obtained on a HP 8453 spectrometer. Platinum analysis was performed by flameless atomic absorption spectroscopy on a Perkin-Elmer AAnalyst 600 system. Analytical and preparative HPLC were run on an Agilent 1200 HPLC system. SequaGel concentrate used in the preparation of the denaturing polyacrylamide gels was purchased from National Diagnostics. 
Synthesis of Platinated Oligonucleotides for the Construction of 146-bp DNA Duplexes
The small DNA duplexes containing a cisplatin ICL or 1,2-d(GpG) cross-link were synthesized and purified by HPLC following the protocol reported previously (14, 28) . The platinated 21-mer strands were characterized by UV-vis spectroscopy, atomic absorption spectroscopy, and a nuclease S1 digestion assay (data not shown). The cisplatin ICL was characterized by 12% polyacrylamide gel electrophoresis ( Figure S2 ) and stored in 0.1 M NaClO 4 at -80 °C.
Preparation of 146-bp DNA Duplexes 63-Mer, 57-mer, 62-mer, and 56-mer oligonucleotides were chemically synthesized and purified by 8% preparative denaturing PAGE.
The purified strands were quantified by UV-vis spectroscopy. The strands were also radiolabeled with [γ- by ethanol precipitation and the ligation products were purified and characterized by a 5%
denaturing PAGE ( Figure S6 ).
Purification of Native Oligonucleosomes
High molecular weight chromatin from HeLa cells was isolated and oligonucleosomes with linker histone depletion were prepared as reported previously (11) . The purity of the oligonucleosomes was confirmed by a 1.5% native agarose gel and a 12% SDS-PAGE ( Figure S7 ).
Nucleosome Reconstitution
Nucleosome reconstitution experiments were carried out as reported previously (11) . Details are reported in the Supplementary Information section.
Vector Construction and Preparation An unreplicable mammalian vector expressing
Gaussia luciferase, pGLuc, was derived from pCMV-GLuc as reported previously (23) . The backbone for construction of Gaussia luciferase plasmids containing site-specific platinum-DNA 1,2-d(GpG) cross-links, pGLuc4temGG, was derived from pGLuc plasmid as described cross-links and the control plasmid with no platinum were synthesized according to a published protocol (23) .
Transient Transfection of Cells and GLuc Reporter Transcription Assays Transient transfection of different mammalian cells and GLuc reporter transcription assays were carried
out following protocols published previously (25) .
Results

Synthesis of Site-Specifically Platinated Nucleosomes
To build site-specifically modified nucleosomes containing different platinum lesions, we adopted the sequence used previously in our laboratory to study the structure of nucleosomal DNA containing a cisplatin 1,3-d(GpTpG) cross-link (10) . This sequence has a moderate affinity for histone octamers and does not form a well-positioned nucleosome (10) . In order to synthesize 146-bp DNAs containing site-specific platinum lesions, small 21-mer/33-mer duplexes containing a cisplatin ICL or a cisplatin intrastrand cross-link were first prepared and purified ( Figures S1 and S2) . The larger strands, 63-mer, 57-mer, 62-mer, and 56-mer, were synthesized, purified, and characterized by a 12%
denaturing PAGE to confirm their purity ( Figure S3 ; sequences shown in Figure S4 ). The 63-mer and 57-mer, and the 62-mer and 56-mer, were annealed in a pairwise fashion to obtain the larger duplexes, which were then annealed and ligated with the small duplexes to yield site-specific 146-bp strands ( Figure S5 ). During this process, [γ-32 P]-ATP was used to label the 5'-end of the 63-mer so that, in the final products, the duplexes were radiolabeled on the top strand. The synthesized site-specific 146-bp strands were characterized on a 5% denaturing gel ( Figure S6 ).
The duplex containing a cisplatin ICL had reduced migration, confirming the presence of a sitespecific ICL. When the ICL was treated with NaCN, the platinum link was removed, converting the duplex into 146-mer strands having the same migration as duplexes containing no platinum ( Figure S6 ). Native oligonucleosomes containing core histones with linker histone depletion from HeLa cells were purified ( Figure S7 ) (11) . First, we transferred the labeled duplexes with or without a site-specific cisplatin ICL to donor chromatin having >3 nucleosomes, 2-3 nucleosomes, or 1-2 nucleosomes. The transfer efficiency for the centered, radiolabeled forms of the nucleosome core particle (NCP) assembly and off-centered NCP assembly was similar when different sizes of chromatin were utilized ( Figure S8 ). We therefore used donor chromatin having 2-3 nucleosomes in the following assays.
Effects of Cisplatin ICLs on Nucleosome Repositioning
When the NCP samples were heated at 45 °C for 2 h, most of the off-centered NCPs containing no platinum shifted to form centered NCPs. NCPs containing a site-specific cisplatin ICL were, however, unable to be heat shifted to form centered NCPs, indicating that a cisplatin ICL alters nucleosome mobility ( Figure   S8 ). We next examined, in much greater detail, the influence of a cisplatin ICL on the dynamic behavior of nucleosome in solution by testing its effect on nucleosome repositioning induced by (from 40% to 50%). Secondly, heat shifting converted only a small portion of off-centered to centered nucleosomes, even after 3 h at both 37 °C and 45 °C. The transfer speed was higher at the higher temperature, but still a large portion of the nucleosomes remained in the off-centered form ( Figure 2 and Figure S9) . A quantitative analysis of the influence of different platinum adducts on nucleosome positional preference is shown in Figure 3 . The overall strategy for constructing a site-specific ICL plasmid is given in Figure 5 . The acceptor plasmid pGLuc-Bsm2 was first linearized by digestion with HindIII and then purified ( Figure 5, a and b) . A 100-fold molar excess of the phosphorylated heteroduplex oligonucleotide containing a site-specific ICL, as shown in Figure 4 , was annealed to the linearized pGLuc-Bsm2 in the presence of T4 DNA ligase. Because these oligos contain a 5'-AGCT overhang complementary to the HindIII-generated ends, they could be annealed to the linearized pGLucBsm2 in a specific direction. This is a dead-end reaction because the HindIII ligation site was eliminated after the addition of the heteroduplex, with the resulting linearized plasmid containing two 5'-CCCT overhangs that could not be annealed and ligated to form a circularized plasmid.
Construction of pGLuc Containing Site-Specific ICLs
The excess amount of small oligos was eliminated. The next step required removal of the platinated heteroduplex oligonucleotide from one end of the plasmid to generate a ligationcompetent plasmid end suitable for recircularization ( Figure 5, c ). In the current design, the heteroduplex contains a 5'-CCCT overhang complementary to that generated by BsmBI digestion. We used size exclusion chromatography to remove the smaller DNA fragments, because they could potentially affect the subsequent annealing and ligation steps ( Figure 5 , d).
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This purified linear plasmid contains a 5'-CCCT overhang from the inserted small oligo and a 5'-AGGG overhang from the BsmBI digestion, and it could therefore be closed by T4 DNA ligase.
The ligation was carried out at low plasmid concentrations to favor formation of circular products by intramolecular rather than intermolecular reactions, thereby avoiding the formation of multimers ( Figure 5, e) . The final site-specific circular plasmid, pGLuc9temG+ICL, was purified by isopycnic ultracentrifugation (Figure 5, f) . With this strategy, a heteroduplex oligonucleotide containing a site-specific cisplatin ICL could be incorporated into the pGLuc plasmid in a specific direction. In parallel we synthesized a control plasmid incorporating a heteroduplex oligonucleotide containing no platinum, designated pGLuc9temG+IS. Restriction digestion analysis of the synthesized and purified plasmids ( Figure S10 ) confirmed their purity and the successful incorporation of an ICL. cross-links and pyriplatin-DNA lesions has been previously described (24, 25) . A growing body of evidence has shown that NER may also function in the repair of ICLs. Several NER components, including XPF·ERCC1 and RPA, participate in ICL repair in vitro (38) . NER makes dual incisions in E. coli and yeast, bracketing the ICL on one of the cross-linked strands to "unhook" the cross-link (39, 40) . Other evidence reveals, however, that NER is dispensable in mammalian ICL repair (41) . Unlike the NER-defective mutants in E. coli and yeast, the 
Transcription Inhibition at Cisplatin ICLs in NER-Proficient and -Deficient Cells
Role of MMR in the Repair of Cisplatin-DNA Cross-Links
Besides the direct role of MMR in DNA repair, it triggers apoptosis signaling pathways following platinum-DNA damage (46) . MMR, which contributes to cisplatin resistance (47, 48) , is involved in eliminating ICLs formed by psoralen in human cells (49) . The role of MMR proteins in processing cisplatin ICLs has also been investigated. In particular, we showed in an electrophoretic mobility shift assay that hMutSβ, a heterodimer of hMSH2 and hMSH3, binds to a cisplatin ICL (14) . In addition, transcription assays with globally platinated pGLuc plasmids reveal that the transcription inhibition following cisplatin and pyriplatin damage is greater in hMSH2-proficient cells (25) . A previous study reported greater gene-specific repair efficiency of cisplatin inter-but not intrastrand cross-links that was linked to cisplatin resistance (17) . Because of their unique structure, however, cisplatin ICLs are more challenging for the cellular repair machinery to eliminate. A detailed repair mechanism for ICLs is not fully worked out, and recent work has identified replication-dependent repair of ICLs in which the Fanconi anemia (FA) pathway plays a pivotal role (16, 50) . Little is known about the replication-independent repair mechanism of ICLs and their influence on nucleosomal DNA. We find here that cisplatin ICLs inhibit DNAhistone sliding and therefore potentially shield themselves from cellular repair. Cisplatin ICLs strongly inhibit transcription to an extent not less than that of cisplatin 1,2-d(GpG) cross-links.
NER plays a role, albeit not a significant one, in the replication-independent repair of cisplatin ICLs, and loss of MMR function greatly attenuates the transcription inhibition effects of cisplatin ICLs but not 1,2-d(GpG) intrastrand cross-links. These findings, together with our previously published work (14) , confirm that cisplatin ICLs are uniquely recognized by nuclear proteins, strongly inhibit transcription in live mammalian cells, and have special pathways for removal.
Owing to these unique properties, we now speculate that cisplatin ICLs may also contribute significantly to the cytotoxicity of cisplatin as well as to cellular resistance to the drug. The manner by which cells process cisplatin ICLs will therefore dramatically affect the 20 pharmacological activity of cisplatin. More detailed studies of the cellular processing of cisplatin ICLs, such as an in-depth analysis of replication-dependent and -independent repair mechanisms at the nucleosome level, should provide a more complete picture of the mechanism of action of cisplatin, the "penicillin" of modern chemotherapeutics, and offer information regarding resistance to this drug. Such information will also guide the design of future generation platinum-based antineoplastic agents with improved pharmacological activities and reduced side effects.
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